Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2086 placebo-controlled randomized trial in adults with narcolepsy
2025-523503-30-00Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in narcolepsy, narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) comparing E2086 with Placebo (2 arms). Primary endpoint: Change from Baseline to Week 4 in MSL across four MWTs. Started Jul 2026; status: completed.
02
Drugs
E2086
03
Conditions
narcolepsynarcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on 2025-523503-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523503-30-00.